Prostate Cancer Takes Center Stage at the ASCO GU Symposium 2023

By Zachary Bessette - Last Updated: January 19, 2023

On the first day of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2023, attendees will gather for a general session on advanced prostate cancer.  Gerhardt Attard, MD, PhD, FRCP, University College London Cancer Institute, will kick things off with a presentation on treatment combination for patients starting androgen-deprivation therapy (ADT), followed by sessions on treatment sequencing and new targets for metastatic castration-resistant disease as well as updated data on a few clinical trials in this area.

The mid-day general session comprises general discussions on treating localized prostate cancer, including novel guidelines for PSMA PET staging of disease, novel approaches for risk stratification, and active surveillance for favorable intermediate-risk disease.

The final general session of the day features a presentation—followed by a moderated panel discussion—on testosterone recovery in prostate cancer patients treated with radiotherapy and different ADT duration.

Post Tags:ASCO GU 2023-Prostate Cancer